FDA Approval Summary: Belzutifan for VHL Disease Tumors-Response

Clin Cancer Res. 2023 Feb 1;29(3):685. doi: 10.1158/1078-0432.CCR-22-3428.

Authors

Jaleh Fallah¹, Chana Weinstock¹, Gautam U Mehta¹, Michael H Brave¹, William F Pierce¹, Richard Pazdur^{1

2}, Abhilasha Nair¹, Daniel L Suzman¹, Laleh Amiri-Kordestani¹

Affiliations

¹ Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
² Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland.

PMID: 36722139
DOI: 10.1158/1078-0432.CCR-22-3428

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Von Hippel-Lindau Tumor Suppressor Protein* / genetics

Substances

belzutifan
VHL protein, human
Von Hippel-Lindau Tumor Suppressor Protein